Investigational drug · Phase 2
BI 1819479
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
6
Any phase or sponsor naming "BI 1819479"
First trial start
2024
Sep 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 1819479", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 1819479" as an intervention, largest first.
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06335303 · 322 participants · Start Sep 5, 2024 · Primary completion Nov 25, 2025
Drug: BI 1819479; Placebo matching BI 1819479 · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Lakewood, Colorado; Kissimmee, Florida · 163 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT04801693 · 66 participants · Start May 26, 2021 · Primary completion Apr 25, 2022
Drug: BI 1819479; Placebo · For: Healthy
Sites: Mannheim, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT05440799 · 62 participants · Start Jul 20, 2022 · Primary completion Aug 2, 2023
Drug: BI 1819479; BI matching placebo · For: Healthy
Sites: Mannheim, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT05469646 · 24 participants · Start Aug 3, 2022 · Primary completion Dec 20, 2022
Drug: BI 1819479; Matching placebo · For: Healthy
Sites: Tokyo, Sumida-ku, Japan
- A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the BloodCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT05467475 · 15 participants · Start Oct 18, 2022 · Primary completion Jan 23, 2023
Drug: BI 1819479; Esomeprazole · For: Healthy
Sites: Biberach, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT07065617 · 7 participants · Start Aug 4, 2025 · Primary completion Oct 4, 2025
Drug: [14C]BI 1819479; BI 1819479 and 1 more · For: Healthy
Sites: Nottingham, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Design of a phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis.
Wuyts WA, Bonella F, Ishii H, et al. · ERJ Open Res 2026
Also in development for Idiopathic Pulmonary Fibrosis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Inhaled TreprostinilLIQ861 Inhaled Treprostinil, Inhaled prostacyclinPhase 35 trials
United Therapeutics · Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- BMS-986278AdmilparantPhase 33 trials
Bristol Myers Squibb · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- BI 1015550Phase 32 trials
Boehringer Ingelheim · Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis
- DeupirfenidonePhase 32 trials
PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- INS018_055Phase 32 trials
InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- REGEND001Phase 32 trials
Regend Therapeutics · COPD (Chronic Obstructive Pulmonary Disease), Idiopathic Pulmonary Fibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.